Recent clinical trial results have revealed that adults taking Zepbound achieve significantly more weight loss than those using competitor medication Wegovy. Conducted by Eli Lilly, the SURMOUNT-5 phase clinical trial compared both GLP-1 medications for the first time, highlighting considerable differences in outcomes between the two drugs.
Zepbound, which contains tirzepatide, not only mimics the GLP-1 hormone responsible for appetite regulation but also targets another hormone, called GIP. This dual mechanism may contribute to the enhanced weight loss seen in users of Zepbound. Over the course of a year and a half, participants using Zepbound experienced an average weight reduction of approximately 20%. In comparison, those on Wegovy lost around 14% of their body weight in the same timeframe.
Specifically, the data indicates that Zepbound users lost about 50 pounds, while Wegovy users averaged a loss of 33 pounds. Furthermore, a higher percentage of Zepbound users, approximately 32%, achieved a milestone of losing at least 25% of their body weight, compared to only 16% of Wegovy users reaching this target.
Leonard C. Glass, senior vice president of global medical affairs at Lilly Cardiometabolic Health, emphasized the importance of these findings. He noted, “Given the increased interest around obesity medications, we conducted this study to help health care providers and patients make informed decisions about treatment choice.” Zepbound is notable as the only FDA-approved obesity medication that functions as a dual GIP and GLP-1 receptor agonist, indicating a significant advancement in the management of obesity.
The results from this clinical trial are set to be published in a peer-reviewed journal and will be presented at a medical meeting in 2025, providing more insights into the effectiveness of these weight management options.
In response to these findings, a spokesperson for Novo Nordisk highlighted the importance of Wegovy, citing its benefits in reducing cardiovascular risks for individuals with obesity and heart disease. They reiterated that people living with obesity deserve comprehensive solutions and support, emphasizing that obesity treatment should extend beyond mere weight reduction.
Source: Yahoo News UK
